Results 131 to 140 of about 344,749 (312)

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

open access: yesMolecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung   +17 more
wiley   +1 more source

Pahiatua borough : the formative years (1881-1892) : a thesis presented in partial fufilment of the requirements for the degree of Master of Arts in History at Massey University [PDF]

open access: yes, 1973
To the New Zealand citizen of the 1970's, surrounded either by the tall buildings of an urban landscape, or the predominantly open fields of a rural environment, the terms Seventy and Forty mile bush may connote more of a legendary forest tract, than the
Bentley, Byron John
core  

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

open access: yesMolecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon   +4 more
wiley   +1 more source

Normal forms for periodic systems

open access: yesJournal of Mathematical Analysis and Applications, 1986
The author develops the theory of normal forms for t-periodic vector fields, fleshing out a brief description of the theory in the book by \textit{V. I. Arnold}, Geometrical methods in the theory of ordinary differential equations (1983; Zbl 0507.34003).
openaire   +2 more sources

Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra   +6 more
wiley   +1 more source

Transformación del paisaje social en Arica, norte de Chile: De pescadores arcaicos a agricultores incipientes

open access: yesEstudios Atacameños, 2012
El proceso de cambio de una sociedad de pescadores- recolectores,como los grupos Chinchorro, hacia una sociedad agrícola más sedentaria, como se ha planteado para las poblaciones Faldas del Morro y Alto Ramírez, no solo implicó un cambio en la ...
Iván Ricardo Muñoz Ovalle   +1 more
doaj  

Home - About - Disclaimer - Privacy